cepheid produc supernorm revenu growth diagnost segment
maintain buy rate upgrad tp
deriv estim base forward
earn multipl ep give
upsid potenti also
estim top line revenu growth
cepheid team embrac two key commerci db
growth tool transform market funnel manag
believ cepheid continu expand lead market
posit gain market share
beckman team continu take market share driven
improv commerci execut new product innov
octob dhr life scienc platform success close
acquisit idb softwar informat leader life
scienc space platform combin life scienc
instrument enabl research acceler
innov effort help make better faster scientif
declin tradit consum growth rate start
moder howev dhr equip busi neg
impact recent realign certain distributor
manufactur relationship compani anticip
difficult market condit persist
top-lin growth beat revenu
estim strong growth net margin beat
adjust ep estim
mn except ep crispidea name corporationtickerdhrstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep gin gin ttm per share growth profit ttm ttm incom ttm earn growth corp ch
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
revenu quarter compar
increas y/i led
increas demand compani product servic
overal basi togeth compani continu
invest sale growth initi
compani acquir ten busi total
consider cash busi acquir
complement exist unit compani life scienc
dental environment appli solut segment
aggreg annual sale ten busi time
respect acquisit case base
compani revenu last complet fiscal year prior
acquisit
guidanc compani chang full year
guidanc strong revenu growth quarter
increas full year ep expect
previou guidanc
expect adjust ep
price-to-earnings seen stun growth sinc cross
average mean level even cross standard
deviat level ep stabl slowli
grow last year price increas
drastic lead constant increas
seen stun growth stock price
increas one year led strong busi
perform segment acquisit cepheid
push revenu growth diagnost
segment estim strong perform continu
maintain buy rate
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short n/a short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date apr ex-dividend date dec last split factor new per last split date jul inform danah corp march
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
incom statement item month end month end month end month end month end month end month end month end month end month end month end revenu total- total revenu gross selling/general/admin expens research depreciation/amortization- interest expens incom net operating- unusu expens incom oper expens total- total oper oper interest incom expens net loss sale assets- net- incom incom minor interest- equiti affiliates- net incom extra account change- discontinu operations- extraordinari item- net prefer dividends- incom avail common excl extra incom avail common incl extra basic weight averag shares- basic ep exclud extraordinari items- basic ep includ extraordinari items- dilut dilut weight averag dilut ep exclud extraordinari dilut ep includ extraordinari items- dividend per share common stock primari gross dividend common stock- net incom stock base comp expense- basic ep stock base comp expsense- dilut ep stock base comp expense- depreci supplemental- total special items- normal incom taxes- effect special item incom taxes- incom tax ex impact special items- normal incom taxes- normal incom avail common- basic normal eps- dilut normal actual annual estim annual actual quarterli corp march
 short term investments- short term account receiv trade receiv other- total receiv total prepaid current asset total- total current property/plant/equip total goodwil intang long term long term asset total account accru note payable/short term debt- current port lt debt/capit current liabil total current long term capit leas total long term total defer incom tax- minor liabil total redeem prefer stock total- prefer stock non redeem net- common stock addit paid-in retain earn accumul treasuri stock common- equiti total total liabil sharehold share out common stock primari issue- total common share actual annual actual quarterli balanc sheet item danah corp march
oper cash flow continu oper increas due primarili higher
earn also includ higher non-cash charg depreci amort increas
partial off-set gain sale market equiti secur increas cash flow
use trade account receiv inventori account payabl
decemb compani held cash cash equival compar
decemb
net cash use invest activ consist primarili cash paid acquisit
addit properti plant equip compani acquir ten busi total
consider includ assum debt net cash acquir payment addit
pp increas includ invest oper asset particularli new facil
oper asset newli acquir busi use cash partial off-set proce
sale invest includ cash proce sale certain market
month end month end month end month end month end month end month end month end income/start work oper invest item invest dividend retir stock retir debt financ exchang chang interest paid tax paid revenu
quarter
compar
increas y/i
 expens
quarter
compar
net incom
compar
increas
y/i ep
basi
increas
y/i compar
post brilliant number top-lin grow y/i led
increas demand product servic overal busi
cepheid acquisit show better expect result
diagnost busi adjust ep quarter beat
estim
revenu quarter compar
increas y/i led increas demand compani
product servic overal basi togeth compani continu
invest sale growth initi business-specif factor
cog quarter compar
increas y/i primarili due impact higher y/i sale volum
includ sale recent acquir busi gross margin
increas compar
 expens quarter compar
increas y/i increas due primarili higher expens
percentag sale busi recent acquir particularli
cepheid well continu invest new product develop
sg quarter compar
increas y/i increas driven higher rel spend level
recent acquir compani primarili cepheid continu invest
sale market growth initi partial off-set benefit increas
leverag compani gener administr cost base result
ebit quarter compar
increas y/i increas due higher percent increas
revenu oper expens oper margin
compar
net incom compar
increas y/i net margin stood quarter
increas due increas oper incom ep
basi increas y/i compar
total revenu compar
increas y/i sale acquir busi increas y/i basi
primarili due acquisit cepheid currenc
translat posit impact
cog compar increas
y/i gross margin increas compar
increas due impact higher y/i sale volum
includ sale recent acquir busi impact
restructur impair relat charg associ
compani strateg decis discontinu product line diagnost
total revenu
compar
increas
 expens
compar
increas
 expens compar
increas y/i increas due primarili higher expens
percentag sale busi recent acquir primarili
cepheid well y/i increas spend compani new product
net incom
compar
net
margin
compar
ep
compar
sg compar increas
y/i decreas sg percent sale due increas
leverag compani gener administr cost base result
higher sale volum continu product improv taken
ebit compar increas
y/i increas due higher percent increas revenu increas
oper expens oper margin compar
net incom compar net
margin compar ep
compar
danah report segment consist life scienc diagnost dental
total revenu life scienc segment quarter
compar increas y/i
total revenu life scienc segment quarter
compar increas y/i price increas segment
contribut revenu growth
sale busi broad rang mass spectromet continu grow
y/i basi led strong sale growth pharmaceut market across asia
north america well sale growth food forens market
across major region growth partial off-set continu declin
demand clinic market north america
sale microscopi product increas y/i basi growth demand
across end-market particularli western europ high-growth
market y/i sale busi flow cytometri particl count product
grew primarili due new product introduct led
increas sale north america western europ china
sale filtrat separ purif technolog grew y/i
basi led continu growth biopharmaceut microelectron
partial off-set declin process industri medic product
particularli
oper profit quarter compar
increas y/i increas primarili due higher
volum sale increment y/i cost save associ restructur
action continu product improv initi taken
oper margin compar
oper profit compar
total revenu
life scienc segment
quarter
compar
y/i price increas
segment contribut
revenu growth
sale microscopi
product increas
y/i basi growth
demand across
western europ
high-growth market
oper profit
quarter
compar
increas y/i
total revenu diagnost segment quarter
compar increas y/i price chang
segment modestli benefit sale growth y/i basi quarter
total revenu diagnost segment compar
increas y/i price chang segment modestli
benefit sale growth y/i basi acquisit cepheid
novemb contribut major increas sale
sale clinic lab busi increas year-over-year basi
geograph continu strong demand high-growth market clinic
lab busi partial off-set declin western europ japan
increas demand immunoassay product line drove major
growth year clinic lab busi growth acut care diagnost
busi driven continu strong consum sale across
major geographi
increas demand advanc stain core histolog instrument
relat consum across major geographi drove major y/i
core sale growth patholog diagnost busi
oper profit quarter increas compar
oper margin quarter
compar due increas sale volum
increment y/i cost save associ restructur action
continu product improv initi taken net increment
y/i cost associ variou new product develop sale servic
oper profit increas compar
oper margin compar
total revenu
diagnost segment
compar
increas
increas demand
line drove major
growth year
clinic lab
oper profit
quarter increas
compar
oper margin
quarter
compar
total revenu quarter compar
increas y/i price increas modestli benefit sale growth y/i
basi quarter
total revenu compar price
increas segment signific impact sale growth
geograph y/i core revenu growth strong china russia
high-growth market off-set lower demand western europ
strong y/i growth continu specialti consum busi
consist implant solut orthodont product
sale growth specialti consum busi led high-growth
market north america dental equip core sale essenti flat
increas demand high-growth market off-set weaker
demand unit state western europ
demand lower tradit dental consum product line north
america western europ reflect inventori destock sever
distribut partner impact inventori destock
consum busi began lessen late recent realign
distributor manufactur dental industri primarili north america
may continu neg impact revenu near-term
oper incom decreas y/i compar
oper margin
compar due increment y/i cost associ
variou new product develop sale market growth invest
unfavor product mix due lower sale dental consum net
increment y/i cost save associ restructur action
continu product improv initi taken
oper incom decreas y/i compar
oper margin compar
total revenu
quarter
compar
y/i basi
demand lower
north america
destock sever
compar
oper margin
compar
total revenu
compar
increas
y/i core sale
line grew increas
demand industri
municip end-
market partial
off-set lower demand
environment
oper profit
compar
oper margin
quarter decreas
compar
total revenu quarter compar
increas y/i price increas segment contribut
sale growth y/i basi quarter
total revenu compar
increas y/i price increas segment contribut sale
growth y/i basi
sale segment water qualiti busi grew low-singl digit rate
y/i core sale analyt instrument product line grew
increas demand industri municip end-market partial off-set
lower demand environment end-market
geograph y/i core revenu growth analyt instrument product
line driven increas demand china western europ north
america partial off-set lower demand middl east latin america
sale segment product identif busi grew mid-singl
digit rate continu strong demand mark code
equip relat consum major geographi led north
america western europ drove major core revenu growth
oper profit compar
oper margin quarter decreas compar
primarili due increment y/i cost associ variou
new product develop sale market growth invest net
posit impact higher core sale volum increment y/i cost save
associ restructur action
oper profit compar
oper margin decreas compar
guidanc conclus
expect core revenu growth
expect adjust ep assum
core growth
expect adjust ep
end stun perform top line
y/i growth seen across busi segment
diagnost led way growth quarter
geograph high growth market grew high singl digit china
india continu lead way develop market saw acceler
us western europ mid-singl digit
help db tool laetu gener greater market awar
demand within pharmaceut track vertic believ
well posit growth go forward
sinc cepheid acquisit achiev basi point gross margin
expans increas oper margin break-even
mid-teen improv on-tim deliveri basi point
oper margin net margin quarter
ttm basi respect roa roe stood ttm
basi respect ep basi quarter
adjust ep
help db
tool laetu
market awar
demand within
vertic believ
well posit
roa roe stood
ep basi
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
ep growth ttm significantli increas compar
revenu growth ttm compar
tax rate reduc ttm
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth corp march
mrqgross mrqcog mrqsg mrqr mrqoper mrqnet margin danah corp march
inv flow sale
mrqfinanci mrqreturn mrqreturn mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale corp march
per share item ratio
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item danah corp march
balanc sheet item
outstand equival market properti plant properti plant issuanc prefer issuanc chang price-to-earnings
price-to-earnings seen stun growth sinc cross average mean level even cross
standard deviat level ep stabl slowli grow last year
price increas drastic lead constant increas price-to-earnings
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held insid share held institut mutual fund float held institut mutual fund institut hold direct holder form daniel thoma patrick donald jame alan angela institut holdersholdershar report outvaluepric row associ vanguard group inc massachusett servic fmr wellington manag compani morgan america parnassu invest top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard parnassu equiti price row capit appreci spdr etf vanguard institut fund-institut price row chip growth fund mf seri trust i-mf valu ishar fidel competit
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
outperform
return
gross margin
slightli higher
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit corp march
consensu view analyst trend stock
rate expect
higher
growth rate
dhr forward price-to-earnings
grow
increas
dhr avgfive-year growth forecast usdgrowth high day day day estim comparisondhrindustri avg avgprice/earn yield corp march
consensu view analyst trend stock
earn growth estim
revenu growth estim
respect
adjust ep estim
estimatescurr analyst estimatethi estim estimatepast ep growthpeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last daysn/an/an/an/a current surprisescurr growth rate corp march
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
chart show price dip feb suggest short squeez share
stock given total return last month
stock reach high jan given total return last year
stock seen steadi rise price stock trade around level
stock increas consist volum trade decreas sinc
stock given total return last year
seen stun growth stock price increas one year led strong busi
perform segment acquisit cepheid push revenu growth
diagnost segment estim strong perform continu maintain buy rate
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
